Literature DB >> 18286587

The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition.

James J Crowley1, Richard S E Keefe, Diana O Perkins, T Scott Stroup, Jeffrey A Lieberman, Patrick F Sullivan.   

Abstract

The neuregulin 1 (NRG1) promoter single nucleotide polymorphism (SNP) rs6994992 has shown association with decreased activation of frontal and temporal lobe regions, increased risk of psychosis, and decreased premorbid IQ. This SNP is part of a putative schizophrenia risk-associated haplotype and was associated with increased expression of the type IV transcript in postmortem tissue. We tested for association between rs6994992 and chronic schizophrenia by genotyping 738 cases from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and 733 matched controls. We further tested for associations with age at onset and baseline neurocognition in cases with schizophrenia reasoning that these phenotypes might yield results similar to those seen for premorbid IQ. Affection status was weakly associated with rs6994992 genotypes and trended towards association under a recessive model. This association did not survive correction for multiple comparisons and was in the opposite direction than has been reported. There was no association between rs6994992 and age at onset, an estimate of premorbid IQ, or neurocognition at study baseline. We were unable to replicate previous associations of rs6994992 with schizophrenia and, moreover, did not find significant associations with age of onset, an estimate of pre-morbid IQ, or neurocognition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286587      PMCID: PMC3875465          DOI: 10.1002/ajmg.b.30727

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  12 in total

1.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay.

Authors:  K J Livak
Journal:  Genet Anal       Date:  1999-02

2.  Sample size requirements for association studies of gene-gene interaction.

Authors:  W James Gauderman
Journal:  Am J Epidemiol       Date:  2002-03-01       Impact factor: 4.897

3.  Estimating premorbid intelligence: comparison of traditional and contemporary methods across the intelligence continuum.

Authors:  Stefanie L Griffin; Monica Rivera Mindt; Eugene J Rankin; A Jocelyn Ritchie; James G Scott
Journal:  Arch Clin Neuropsychol       Date:  2002-07       Impact factor: 2.813

4.  Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia.

Authors:  Dawei Li; David A Collier; Lin He
Journal:  Hum Mol Genet       Date:  2006-05-10       Impact factor: 6.150

5.  Association of neuregulin 1 with schizophrenia confirmed in a Scottish population.

Authors:  Hreinn Stefansson; Jane Sarginson; Augustine Kong; Phil Yates; Valgerdur Steinthorsdottir; Einar Gudfinnsson; Steinunn Gunnarsdottir; Nicholas Walker; Hannes Petursson; Caroline Crombie; Andres Ingason; Jeffrey R Gulcher; Kari Stefansson; David St Clair
Journal:  Am J Hum Genet       Date:  2002-12-11       Impact factor: 11.025

6.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

7.  Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease.

Authors:  Amanda J Law; Barbara K Lipska; Cynthia Shannon Weickert; Thomas M Hyde; Richard E Straub; Ryota Hashimoto; Paul J Harrison; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-17       Impact factor: 11.205

8.  Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Authors:  Richard S E Keefe; Richard C Mohs; Robert M Bilder; Philip D Harvey; Michael F Green; Herbert Y Meltzer; James M Gold; Mary Sano
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

9.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

10.  A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms.

Authors:  Jeremy Hall; Heather C Whalley; Dominic E Job; Ben J Baig; Andrew M McIntosh; Kathryn L Evans; Pippa A Thomson; David J Porteous; David G Cunningham-Owens; Eve C Johnstone; Stephen M Lawrie
Journal:  Nat Neurosci       Date:  2006-10-29       Impact factor: 24.884

View more
  15 in total

1.  Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Authors:  Anna C Need; Richard S E Keefe; Dongliang Ge; Iris Grossman; Sam Dickson; Joseph P McEvoy; David B Goldstein
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

Review 2.  Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome.

Authors:  Anamika Banerjee; Mathew L Macdonald; Karin E Borgmann-Winter; Chang-Gyu Hahn
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 3.  The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits.

Authors:  Andrés Buonanno
Journal:  Brain Res Bull       Date:  2010-08-03       Impact factor: 4.077

4.  Molecular and cellular characterization of Neuregulin-1 type IV isoforms.

Authors:  Alon Shamir; Andres Buonanno
Journal:  J Neurochem       Date:  2010-03-10       Impact factor: 5.372

5.  Genetic associations between neuregulin-1 SNPs and neurocognitive function in multigenerational, multiplex schizophrenia families.

Authors:  Jessica L Yokley; Konasale M Prasad; Kodavali V Chowdari; Michael E Talkowski; Joel Wood; Ruben C Gur; Raquel E Gur; Laura Almasy; Vishwajit L Nimgaonkar; Michael F Pogue-Geile
Journal:  Psychiatr Genet       Date:  2012-04       Impact factor: 2.458

6.  Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population.

Authors:  Emily Moon; Brandi Rollins; Andrea Mesén; Adolfo Sequeira; Richard M Myers; Huda Akil; Stanley J Watson; Jack Barchas; Edward G Jones; Alan Schatzberg; William E Bunney; Lynn E DeLisi; William Byerley; Marquis P Vawter
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

7.  Lack of associations of neuregulin 1 variations with schizophrenia and smooth pursuit eye movement abnormality in a Korean population.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Charisse Flerida A Pasaje; Joon Seol Bae; Chul Soo Park; Boseok Cha; Bong-Jo Kim; Migyung Lee; Woo Hyuk Choi; Tae-Min Shin; Ihn-Geun Choi; Jaeuk Hwang; Insong Koh; Sung-Il Woo; Hyoung Doo Shin
Journal:  J Mol Neurosci       Date:  2011-08-20       Impact factor: 3.444

8.  Genomewide association for schizophrenia in the CATIE study: results of stage 1.

Authors:  P F Sullivan; D Lin; J-Y Tzeng; E van den Oord; D Perkins; T S Stroup; M Wagner; S Lee; F A Wright; F Zou; W Liu; A M Downing; J Lieberman; S L Close
Journal:  Mol Psychiatry       Date:  2008-03-18       Impact factor: 15.992

9.  Neuregulin links dopaminergic and glutamatergic neurotransmission to control hippocampal synaptic plasticity.

Authors:  Jörg Neddens; Detlef Vullhorst; Daniel Paredes; Andres Buonanno
Journal:  Commun Integr Biol       Date:  2009-05

10.  Family-based association study of Neuregulin 1 with psychotic bipolar disorder.

Authors:  Fernando S Goes; Virginia L Willour; Peter P Zandi; Pamela L Belmonte; Dean F MacKinnon; Francis M Mondimore; Barbara Schweizer; Elliot S Gershon; Francis J McMahon; James B Potash
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-07-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.